Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69

Benzinga Newsdesk www.benzinga.com Positive 73.5%

Neg 0% Neu 0% Pos 73.5%

Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $35 to $69.